Thomas Grischott

Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis

Kerstin Noëlle Vokinger, Thomas J. Hwang, Thomas Grischott et al. · The Lancet Oncology · 2020 · 226 citations

Pharmacy, Oncology, Pharmacoeconomics +16

Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe

Kerstin Noëlle Vokinger, Thomas J. Hwang, Paola Daniore et al. · JAMA Oncology · 2021 · 82 citations · Full text

Pharmacy, Oncology, Pharmaceutical Policy +17

Inferior control of low-density lipoprotein cholesterol in women is the primary sex difference in modifiable cardiovascular risk: A large-scale, cross-sectional study in primary care

Yael Rachamin, Thomas Grischott, Thomas Rosemann et al. · Atherosclerosis · 2021 · 50 citations · Full text

Medicine, Preventive Medicine, Disease Prevention +16

Evaluation of the Education “Clinical Telemedicine/e-Health” in the Curriculum of Medical Students at the University of Zurich

Christiane Brockes, Thomas Grischott, M Dutkiewicz et al. · Telemedicine Journal and e-Health · 2017 · 48 citations

Medicine, Health Education, Medical Education +11

The Shiny Balancer - software and imbalance criteria for optimally balanced treatment allocation in small RCTs and cRCTs

Thomas Grischott · BMC Medical Research Methodology · 2018 · 22 citations · Full text

Public Health, Biostatistics, Good Clinical Practice +11